Immunogen (IMGN $14.36) and Roche announced improved overall survival (OS) as well as progression free survival (PFS) in a Phase III trial for its trastuzumab emtansine (T-DM1) drug utilizing Targeted Antibody Payload Technology ( TAP). The trastuzumab (Herceptin) antibody drug conjugate is being developed jointly by Roche and Immunogen and today Roche announced it has submitted a biologics license application (BLA) to the US FDA and soon to the European Medicines Agency (EMA).
bula wellbutrin sr 150mg ImmunoGen IMGN) was added to the Rayno Life Science Portfolio on 12/22/11 at a price of $12.40 and hit a high of $18 on July 9. Biopharmaceutical stocks are just off their July highs (XBI $88.62) in a period of consolidation at the low end of their upward channel. Other Rayno Biopharma stocks up today in a flat market are Tadalafil Tastylia orally disintegrating strips Astex (ASTX $2.84), Cubist (CBST $45.93) and Pharmacyclics (PCYC $67.98).
Another one of our mid-cap biotech picks utilizing antibody-drug conjugates is Seattle Genetics (SGEN $26.65) is up 59.41 % YTD.